Fig. 3From: A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapyGene mutational profiles in the high-SST2 LGG and low-SST2 LGG. Six genes showed genetic alteration in accordance with SST2 status. IDH, CIC, and FUBP1 mutations were more in high-SST2 tumor. On the contrary, EGFR, PTEN, and TP53 mutations were more in low-SST2 tumorBack to article page